Aradigm Corporation Receives U.S. FDA Clearance for Phase 3 Clinical Trial of Pulmaquin™ in Patients with Non-Cystic Fibrosis Bronchiectasis
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (“Aradigm” or the "Company") today announced that the Company’s Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration (FDA).